Abstract P022 – Table 1. Individual subject blood and cerebrospinal fluid parameters at Week 8
Subject | 1 | 2 | 3 | 4 |
---|---|---|---|---|
CSF cenicriviroc concentration, ng/mL | 0.82 | 0.40 | 0.24 (less than LLQ) | 0.24 (less than LLQ) |
Plasma cenicriviroc concentration, ng/mL | 718.6 | 211.1 | 411.9 | 70.5 |
CSF: plasma cenicriviroc concentration ratio (%) | 0.11 | 0.19 | 0.06 | 0.34 |
CSF albumin concentration, mg/mL | 1070 | 453 | 374 | 202 |
Serum albumin concentration, g/L | 38 | 42 | 40 | 40 |
CSF: serum albumin ratio | 28.2 | 10.8 | 9.4 | 5.1 |
Antiretroviral therapy | abacavir, lamivudine, raltegravir | lamivudine, atazanavir, ritonavir | tenofovir DF, emtricitabine, dolutegravir | tenofovir DF, emtricitabine, raltegravir |
Cenicriviroc dose | 150 mg | 50 mg | 150 mg | 150 mg |
tenofovir DF = tenofovir disoproxil fumarate.